Skip Navigation


Japanese Journal of Clinical Oncology Advance Access originally published online on March 4, 2009
Japanese Journal of Clinical Oncology 2009 39(5):327-331; doi:10.1093/jjco/hyp005
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
39/5/327    most recent
hyp005v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Park, K.-S.
Right arrow Articles by Lee, J. S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Park, K.-S.
Right arrow Articles by Lee, J. S.
Related Collections
Right arrow Case Report
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?


© The Author (2009). Published by Oxford University Press. All rights reserved

Sunitinib, a Novel Therapy for Anthracycline- and Cisplatin-refractory Malignant Pheochromocytoma

Kyung-Sun Park1, Jae-Lyun Lee1,4, Hanjong Ahn2, Jung-Min Koh1,3, Inkeun Park1, Jun-Seok Choi1, Yi Rang Kim1, Tai Sun Park1, Jin-Hee Ahn1,4, Dae Ho Lee1,4, Tae Won Kim1,4 and Jung Shin Lee1,4

1 Department of Internal Medicine, University of Ulsan College of Medicine, Asan Medical Center
2 Department of Urology, University of Ulsan College of Medicine, Asan Medical Center
3 Department of Endocrinology, University of Ulsan College of Medicine, Asan Medical Center
4 Department of Oncology, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Republic of Korea

For reprints and all correspondence: Jae-Lyun Lee, Department of Oncology and Department of Internal Medicine, University of Ulsan College of Medicine, Asan Medical Center, 388-1 Poongnap-2 dong, Songpa-gu, Seoul 138-736, Republic of Korea. E-mail: jaelyun{at}amc.seoul.kr

Received October 28, 2008; accepted January 12, 2009

We report a case of malignant pheochromocytoma recurred after debulking surgery. A 17-year-old male patient visited our hospital for right flank pain. He had not experienced palpitations, headache, sweating or weight loss. Level of urinary catecholamine and its metabolite increased above normal values and abdominal computed tomography showed a huge right adrenal mass. One month after debulking surgery, anterior mediastinal and multiple liver metastases were found. These tumors had no response to two conventional regimens of combination chemotherapy (cyclophosphamide, vincristine, dacarbazine and anthracycline; and etoposide and cisplatin). We treated the patient with sunitinib, a multiple tyrosine kinase inhibitor. The tumor showed very good metabolic response to the therapy. In patient with malignant pheochromocytoma, sunitinib might be one therapeutic strategy for malignant pheochromocytomas.

Key Words: malignant pheochromocytoma • sunitinib • combination chemotherapy


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.